Ultralife (NASDAQ:ULBI - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Ultralife to post earnings of $0.23 per share and revenue of $40.00 million for the quarter.
Ultralife Price Performance
Shares of ULBI stock traded down $0.28 during trading hours on Friday, reaching $7.16. The company had a trading volume of 27,722 shares, compared to its average volume of 41,957. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.62 and a current ratio of 3.30. The stock has a fifty day moving average of $7.59 and a 200-day moving average of $8.60. The company has a market capitalization of $119.07 million, a price-to-earnings ratio of 13.02 and a beta of 0.96. Ultralife has a 12-month low of $7.02 and a 12-month high of $13.39.
Analyst Upgrades and Downgrades
Separately, Benchmark restated a "buy" rating and issued a $14.00 price target on shares of Ultralife in a research report on Friday, November 15th.
Get Our Latest Analysis on Ultralife
About Ultralife
(
Get Free Report)
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
See Also
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
